



Contact: Rehab AlJamal-Naylor  
Tel. +44(0)7919-621 733  
Email: [r.aljamal.naylor@avipero.com](mailto:r.aljamal.naylor@avipero.com)

FOR IMMEDIATE PRESS RELEASE

Friday, 17 January 2014.

### **AVIPERO Receives Notice of Allowance for Key Patent from the U.S. Patent Office.**

EDINBURGH, SCOTLAND-Friday, 17 January, 2014-----The board of AVIPERO (Registered in Scotland SC353945) announced today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "COMPOUNDS AND METHODS FOR THE MODULATION OF BETA-1 INTEGRIN FUNCTION TO MEDIATE TISSUE REPAIR " (serial number 12/528,749) patent application.

This patent relates to compounds and methods for the selective allosteric modulation of the ligand binding function of beta1 integrin in order to mediate tissue repair. The invention further extends to methods for the treatment of tissue damage associated with disease conditions such as chronic obstructive pulmonary disease, arthritis, and neurodegenerative conditions.

"This U.S. patent allowance solidifies our intellectual property portfolio for our unique pharmacological targeting method and reinforces our recently granted patents for the same technology." commented Dr. Rehab AlJamal-Naylor, AVIPERO's Chief Scientific Officer.

#### **About AVIPERO Ltd.**

AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. This includes conditions such as Parkinson's disease (PD), chronic obstructive pulmonary disease (COPD), arthritis and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio. Follow us on Twitter @AVIPERO , LinkedIn: <http://www.linkedin.com/company/avipero-ltd> and Facebook: <https://www.facebook.com/pages/Avipero/211039552252904>

#### **Forward Looking Statements**

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO's dependence on collaborative partners and contract research organizations. These factors should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

FOR FURTHER INFORMATION PLEASE CONTACT:

Dr. Rehab AlJamal-Naylor  
AVIPERO Ltd  
Director and CSO,  
+44(0)7919-621-733  
[info@avipero.com](mailto:info@avipero.com)  
[www.avipero.com](http://www.avipero.com)